L&T-TECHNOLOGY-SVCS
L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a global leading pure-play engineering services company, today announced that its award-winning healthcare solution Chest rAI™ in collaboration with global technology leader Intel Corporation.
Chest rAI™ , LTTS’ AI-based chest X-Ray analysis system to assist radiologists in improving speed and accuracy of diagnosis, will be fueled by the Intel OpenVINO Toolkit and AI Analytics Toolkit to run optimized AI inferencing models on 3rd Gen Intel Xeon Scalable processors with built in AI accelerators.
LTTS’ AI-infused solution enables radiologists by fast triaging abnormalities in X-Ray, annotating and automatic report generation with significantly improved performance. The benefits of Chest rAI™ include increased throughput with the ability to extract more actionable information and to reduce waiting time for radiologists.
LTTS recently entered into a strategic engagement with one of the largest teleradiology platforms in India - 5C Network Private Limited, wherein 5C Network will leverage Chest rAI™ to empower radiologists with accurate patient insights while saving time.
Abhishek Sinha, Chief Operating Officer and Member of the Board, L&T Technology Services, said, “The potential of digital engineering in transforming complex age-old problem statements of the healthcare industry into simpler and more sophisticated mechanisms is now available to all, while maintaining patient data privacy by taking advantage of Intel hardware-enhanced security technologies. With more investments and by leveraging our engineering expertise in the medical image processing segment, our commitment is to enable a complete transformation of the Indian public health diagnostics services landscape. This collaboration will benefit millions of people not just in the urban but also in the rural areas.”
Sudhir Bahl, Board Member and Chief Strategy Officer, 5C Network, said, “Our endeavor is to serve as a reliable diagnostic partner with technology enabled decision-making for the healthcare service providers in India. As the next phase of growth, we aim to empower our radiologists with the best of futuristic technologies so that it not only enhances our quality but also empowers them with technology-based support to achieve clinical excellence with reduced turnaround time. With LTTS’ Chest rAI™ on Intel’s AI stack, we aim to reach elevated industry benchmarks.”
Intel’s AI Builders Program is an ecosystem of industry-leading independent software vendors (ISVs), system integrators (SIs), original equipment manufacturers (OEMs), and enterprise end users who want to accelerate the adoption of AI across Intel platforms.
Wei Li, VP and GM of Machine Learning Performance at Intel Corporation, said, “Wherever customers need AI, Intel is already there with 3rd Gen Intel Xeon Scalable processors and an optimized software stack for the complete AI pipeline. With investments in tools, technologies, and a worldwide ecosystem of optimized solutions, we’re making AI more accessible than ever. Through the Intel AI Builders Program, we collaborate with companies across the globe to help bring cutting-edge AI solutions and capabilities to market.”
LTTS’ capabilities on digital technology led new-age innovations for radiologists is industry-leading. Earlier this year, Chest rAI™ was honored by the US-based BIG Innovation Award as an acknowledgement of the path-breaking technology capability possessed by the solution.
To know more about LTTS’ Chest rAI™ solution click here:
https://www.ltts.com/solutions/healthcare/AI-radiography/chest-rAI
About L&T Technology Services Ltd
L&T Technology Services Limited (LTTS) is a listed subsidiary of Larsen & Toubro Limited focused on Engineering and R&D (ER&D) services. We offer consultancy, design, development and testing services across the product and process development life cycle. Our customer base includes 69 Fortune 500 companies and 57 of the world’s top ER&D companies, across industrial products, medical devices, transportation, telecom & hi-tech, and the process industries. Headquartered in India, we have over 16,900 employees spread across 17 global design centers, 28 global sales offices and 69 innovation labs as of June 30, 2021. For more information please visit https://www.ltts.com/ .
Intel, the Intel logo, and other Intel marks are trademarks of Intel Corporation or its subsidiaries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005907/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Making Science Unveils ‘AWAKE’: The AI Venture Studio Industrialising Startup Creation and AI-First Innovative Solutions23.12.2025 20:51:00 CET | Press release
The disruption generated by AI enables the acceleration and industrialisation of the creation of internal solutions and start-ups through centres of excellence in Chicago, Madrid and Tbilisi.This model has already proven its commercial and innovative power through the acceleration of startups like ad-machina, which has multiplied its value by 10 since joining the Making Science ecosystem. Making Science, the global digital acceleration consultancy, today announced the launch of AWAKE Venture Studio. This "AI-first" model represents a new era in systematic innovation, designed to identify, prototype, and scale both internal proprietary solutions and independent AI-native startups with global reach. The launch of AWAKE is motivated by the significant efficiency gains of orders of magnitude that Making Science has already achieved through the internal integration of AI. By applying these methods, the firm has achieved a 2x acceleration in tech feature development reducing time in the depl
FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia23.12.2025 18:07:00 CET | Press release
Deseyne® (vifilcon C) Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia with Extended Depth of Focus (EDOF) Delivers Continuous Vision at All Distances—Redefining Presbyopia Correction The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the first and only Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia utilizing patented Extended Depth of Focus (EDOF) optical design technology, enabling commercial distribution in the United States. Deseyne® delivers smooth, continuous focus across near, intermediate, and distance vision, providing clear, natural vision without compromise. This performance is enabled by Cataltheia’s patented hyper-refractive central zone, engineered to precisely redirect light in a controlled manner. The result is a clear clinical advantage over the only other available contact lens option for presbyopia, multifoc
Aramco Awards SLB Long-Term Contract to Support Kingdom’s Unconventional Gas Production Growth23.12.2025 14:58:00 CET | Press release
Five-year contract to drive innovation in stimulation, intervention, digital and frac automationAgreement underscores gas as a pivotal fuel for global energy demand and a bridge to lower-carbon systems Global technology company SLB (NYSE: SLB) has been awarded a five-year contract by Aramco to provide stimulation services for its unconventional gas fields. This award is part of a broader multi-billion contract, supporting one of the largest unconventional gas development programs globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251223074948/en/ The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources. The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconve
Tabelog, Japan's Largest (*1)Restaurant Search and Reservation Service,Launches Multilingual App for International Visitors23.12.2025 14:00:00 CET | Press release
Experience Japan's Authentic Culinary Scene in Your Language — From Search to Reservation, All on Your SmartphoneRanked No. 1 in Downloads Among "Japanese Gourmet Search Apps" Chosen by International Travelers (*2) Tabelog (https://tabelog.com/en/), Japan's largest restaurant search and reservation service operated by Kakaku.com, Inc., launched its multilingual smartphone application (iOS/Android) for international travelers on Monday, November 17, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251221963753/en/ The Tabelog Multilingual App for International Travelers — Japan's Largest Restaurant Search and Reservation Service With approximately 100 million monthly users(*3), Tabelog is Japan's premier service widely used by Japanese locals for daily restaurant discovery. Its database is unrivaled domestically, featuring information on approximately 890,000 establishments nationwide and over 85 million reviews and photo
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference23.12.2025 12:01:00 CET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST. Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company based in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom